Nasal sprays could be the future of treatment for Parkinson’s disease
Scientists at the University of York have made significant progress in the development of a nasal spray treatment for patients with Parkinson’s disease.
Researchers have developed a new gel that can adhere to tissue inside the nose alongside the drug levodopa, helping deliver treatment directly to the brain.
Levodopa is converted to dopamine in the brain, which makes-up for the deficit of dopamine-producing cells in Parkinson’s patients, and helps treat the symptoms of the disease. Over extended periods of time, however, levodopa becomes less effective, and increased doses are needed.
Increased dosage
Professor David Smith, from the University of York’s Department of Chemistry, said: “The current drug used for Parkinson’s Disease is effective to a point, but after a long period of use the body starts to breakdown the drug before it gets to the brain where it is most needed.
“This means increased dosage is necessary, and in later stages, sometimes, instead of tablets, the drug has to be injected. Investigations into nasal sprays have long been of interest as a more effective delivery because of its direct route to the brain via the nerves that service the nose, but the challenge here is to find a way of making it adhere to the nasal tissue long enough to release a good dosage of the drug.”
The researchers created a gel, loaded with levodopa, that could flow into the nose as a liquid and then rapidly change to a thin layer of gel inside the nose. The method was tested in animal models by a team at King’s College London, where levodopa was successfully released from the gel into the blood and directly to the brain.
Better uptake
Professor Smith said: “The results indicated that the gel gave the drug better adhesion inside the nose, which allowed for better levels of uptake into both the blood and brain.”
The team are now working to incorporate these materials in nasal spray devices to progress to clinical trials in humans. The approach may also be relevant to other neurodegenerative diseases such as Alzheimer’s.
Khuloud Al-Jamal, Professor of Drug Delivery and Nanomedicine from King’s College London, said: “Not only did the gel perform better than a simple solution, but the brain uptake was better than that achieved using intravenous injection of the drug. This suggests that nasal delivery of Parkinson’s drugs using this type of gel may have clinical relevance.”
Original Article: Step-closer to nasal spray drug delivery for Parkinson’s disease
More from: University of York | King’s College London
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Nasal spray drug delivery
- A new nasal spray for migraines promises a clearer head in minutes
A new nasal spray medication called zavegepant, which aims for near-instant relief from migraine headaches, is expected to hit pharmacies later this month or early July.
- Breathe Life into Allergy Emergencies With Neffy Nasal Spray
Studies have shown that epinephrine administered through the nose via Neffy has comparable effects on heart rate, blood pressure, and anaphylaxis symptoms as injection-based devices like EpiPens ...
- Ketamine Nasal Spray Could Be New Treatment for Migraines
Ketamine is a synthetic anesthetic with hallucinogenic effects that is sometimes used intravenously for migraine headaches. It's being tried for treatment-resistant depression, too. But it's also a ...
- Medical marijuana nasal spray now available for purchase in Georgia
Trulieve is the only dispensary in Georgia to sell medical cannabis as a nasal spray. It's already helping patients with a variety of conditions.
- Delivery Device Breathes New Life into Existing Nasal Steroid Treatment
That physiology “creates a different pattern of drug deposition—the same drug ... tested shows you get non-bioequivalence with an exhalation delivery system compared with a standard nasal spray,” he ...
Go deeper with Google Headlines on:
Nasal spray drug delivery
[google_news title=”” keyword=”nasal spray drug delivery” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Parkinson’s Disease
- Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
In its ongoing R&D reorganization, Biogen Inc (NASDAQ: BIIB) will discontinue a Phase 3 program evaluating BIIB122 as a treatment for patients with Parkinson’s disease related to LRRK2 mutations with partner Denali Therapeutics Inc (NASDAQ: DNLI).
- Selvita and the University of Oxford join forces to tackle Parkinson’s disease
The Polish drug discovery and service provider Selvita has announced a new collaboration with the University of Oxford to advance the development of Parkinson’s disease therapies.
- Encouraging results forParkinson's Disease drug in Biovie study as more patients retain sufficient muscle control
Encouraging clinical data has been released by Biovie, a company developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.
- Parkinson’s disease drug ropinirole safely slowed the progression of ALS in clinical trial
In a clinical trial, researchers in Japan reported that the Parkinson's drug ropinirole slowed symptoms in people with ALS over a 6-month period
Go deeper with Google Headlines on:
Parkinson’s Disease
[google_news title=”” keyword=”Parkinson’s Disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
